Aurinia Pharmaceuticals: Advancing the Frontier of Autoimmune Disease Treatment
For patients living with autoimmune diseases, the search for effective, targeted therapies is often a race against time. Aurinia Pharmaceuticals Inc. Is positioning itself at the forefront of this battle, focusing on therapies for autoimmune conditions with high unmet medical needs. From its landmark approval of LUPKYNIS to its strategic expansion through the acquisition of Kezar Life Sciences, the company is aggressively diversifying its portfolio to move beyond a single-product reliance.
LUPKYNIS: A Breakthrough in Lupus Nephritis
The cornerstone of Aurinia’s commercial success is LUPKYNIS (voclosporin). As the first FDA-approved oral calcineurin inhibitor for adult patients with active lupus nephritis (LN), LUPKYNIS represents a significant shift in how this complex kidney inflammation is managed.
The drug’s global footprint has expanded steadily since its initial FDA approval in January 2021. More recently, the company reached another milestone in September 2024, when Japan’s Ministry of Health approved the product for the treatment of lupus nephritis.
Strategic Expansion: The Kezar Life Sciences Acquisition
While LUPKYNIS established Aurinia as a commercial player, the company is now focused on fortifying its pipeline. On March 30, 2026, Aurinia announced a definitive agreement to acquire Kezar Life Sciences. This move is designed to reduce the risks associated with relying on a single commercial product and to integrate immunoproteasome-based therapeutics into its portfolio.
The Terms of the Deal
The merger is structured to provide immediate value to Kezar stockholders while maintaining a stake in future success:
- Cash Payment: Aurinia will acquire all outstanding shares of Kezar for $6.955 in cash per share.
- Contingent Value Right (CVR): Stockholders will receive one non-transferable CVR per share, offering potential future payouts based on the success of the lead asset, zetomipzomib, as well as excess cash and existing collaborations.
The transaction has received unanimous approval from Kezar’s board and is expected to close in the second quarter of 2026.
The Power of Zetomipzomib
The primary driver of this acquisition is zetomipzomib, a first-in-class small molecule that selectively inhibits the immunoproteasome. This novel mechanism allows for a more targeted approach to taming the immune system, specifically targeting rare autoimmune liver diseases.
A Growing Pipeline and Leadership Transition
Beyond the Kezar acquisition, Aurinia continues to develop aritinercept, a dual BAFF/APRIL inhibitor intended for potential utilize across various autoimmune conditions. This multi-pronged approach ensures the company isn’t just treating one disease, but is building a comprehensive platform for autoimmune care.
This strategic pivot coincides with a major leadership change. In March 2026, Kevin Tang was appointed as CEO, leading the company through this era of acquisition and pipeline expansion.
Company Overview and History
Aurinia’s journey began in 1993 as Isotechnika Pharma Inc. In Edmonton, Alberta, Canada. The company evolved significantly in 2013 after acquiring Aurinia Pharma Corp. And rebranding to its current name, shifting its primary focus toward the development of voclosporin.
Today, the company is headquartered in Victoria, British Columbia, and maintains a critical U.S. Commercial hub in Rockville, Maryland. It is publicly traded on the NASDAQ under the ticker AUPH.
- Lead Product: LUPKYNIS (voclosporin), an FDA-approved oral therapy for active lupus nephritis.
- Recent Acquisition: Agreement to acquire Kezar Life Sciences (March 2026) to add zetomipzomib to the pipeline.
- Core Focus: Autoimmune diseases with high unmet medical needs.
- Leadership: Led by CEO Kevin Tang as of March 2026.
- Market Presence: Headquartered in Victoria, BC, with a U.S. Hub in Rockville, MD.
Frequently Asked Questions
What is LUPKYNIS used for?
LUPKYNIS is an oral calcineurin inhibitor approved for the treatment of adult patients with active lupus nephritis, a serious autoimmune condition affecting the kidneys.
What did Aurinia gain from the Kezar acquisition?
The acquisition provides Aurinia with zetomipzomib, a first-in-class immunoproteasome inhibitor designed to treat rare autoimmune liver diseases, helping the company diversify its pipeline.
Where is Aurinia Pharmaceuticals located?
The company is headquartered in Victoria, British Columbia, Canada, and operates a commercial hub in Rockville, Maryland, USA.
As Aurinia integrates Kezar’s assets and continues the development of aritinercept, the company is transitioning from a single-product firm into a diversified powerhouse in the autoimmune therapeutic space.